European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies.
The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.
BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.
HIFU is a highly precise non-invasive type of surgery which uses ultrasound energy to heat and destroy tumours while leaving surrounding healthy tissue intact. The treatment works with immediate benefit and has the potential to reduce side effects compared with current alternative treatments.
Our portfolio company, STORM Therapeutics secures $56 Million Series C financing and doses its first patient in Phase 2 sarcoma trial of STC‑15, its first‑in‑class, oral small-molecule inhibitor of METTL3.
Inivata, a leader in liquid biopsy, today announced that NeoGenomics has agreed to acquire Inivata.
